New Myeloma Treatment Gives 80% Two-Year Survival Hope

A breakthrough immunotherapy combination helped eight in 10 multiple myeloma patients live two years without their cancer worsening, nearly doubling the success rate of standard treatment.

The results from a global trial of over 860 patients offer renewed hope for families facing this difficult blood cancer.